Kidney Disease (Nephropathy) accounted for a 50.6% share of the global clinical trials within the Genito Urinary System And Sex Hormones therapy area in 2021, registering a decrease of 6.5% when compared with the last ten-year average of 57.1% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Kidney Disease
Industry sponsored trials held a 35.9% share of all the clinical trials for Kidney Disease indication in 2021, registering an increase of 6.8% when compared with the ten-year average of 29.1%. Non-industry sponsored trials accounted for a 64.1% share in 2021, marking a decrease of 6.8% over the ten-year average of 70.9%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Kidney Disease trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Kidney Disease trials, accounting for a 52.9% share in 2021, when compared with the five-year average of 47.4% and ten-year average of 40.1%.
North America was at the second position with a 44.9% share in 2021, over the five-year average of 47.5% and ten-year average of 48.8%, followed by Europe with a 37.0% share in 2021, as against five-year and ten-year averages of 34.2% and 36.6% respectively.
South and Central America stood fourth with a 10.9% share in 2021, compared with the five-year average of 6.5% and ten-year average of 5.9%, followed by Middle East and Africa with a 10.1% share in 2021, over five-year and ten-year averages of 6.7% and 7.8% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored Kidney Disease trials, accounting for a 44.9% share in 2021, as against the five-year average of 46.3% and ten-year average of 47.5%.
China held a 27.5% share in 2021, over the five-year average of 16.9% and ten-year average of 10.3%, followed by Spain with a 17.4% share in 2021, compared with the five-year and ten-year averages of 10.6% and 11.2% respectively.
The UK held a 16.7% share in 2021, as against the five-year average of 12.4% and ten-year average of 13.3%.
Germany held a 15.2% share in 2021, over the five-year and ten-year averages of 16.6% and 17.5% respectively.
Top regions of non-industry sponsored Kidney Disease trials
Asia-Pacific was the top region for non-industry sponsored Kidney Disease trials, accounting for a 48.0% share in 2021 when compared with the five-year average of 47.0% and ten-year average of 45.6%.
Europe was at the second position with a 22.0% share in 2021, over the five-year and ten-year averages of 17.9% and 20.4% respectively, followed by North America with a 15.2% share in 2021, as against the five-year average of 16.0% and ten-year average of 17.8%.
Middle East and Africa stood at the fourth position with an 11.2% share in 2021, compared with the five-year average of 17.8% and ten-year average of 15.2%, followed by South and Central America with a 3.6% share in 2021, over the five-year and ten-year averages of 3.0% and 2.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for non-industry sponsored Kidney Disease trials, accounting for a 29.2% share in 2021, as against the five-year average of 21.3% and ten-year average of 16.1%.
The US held a 14.4% share in 2021, over the five-year average of 13.2% and ten-year average of 14.3%, followed by Iran with an 8.4% share, compared with the five-year and ten-year averages of 14.0% and 12.1% respectively.
Thailand held a 4.0% share in 2021, as against the five-year average of 3.2% and ten-year average of 2.3%.
Japan held a 3.6% share in 2021, over the five-year average of 6.7% and ten-year average of 12.6%.
Phase I trials lead industry sponsored clinical trials for Kidney Disease in 2021
Phase I trials held a 45.6% share of industry sponsored clinical trials for Kidney Disease in 2021, over the five-year average of 44.5% and ten-year average of 40.2%.
Phase II trials held a 28.6% share in 2021, as against the five-year average of 29.1% and ten-year average of 29.4%. Phase III trials held a 19.0% share in 2021, compared with the five-year and ten-year averages of 17.7% and 19.9% respectively.
Phase IV trials held a 6.8% share in 2021, over the five-year average of 8.6% and ten-year average of 10.5%.
Phase II trials lead non-industry sponsored clinical trials for Kidney Disease in 2021
Phase II trials held a 39.7% share of non-industry sponsored clinical trials for Kidney Disease in 2021, over the five-year average of 45.2% and ten-year average of 46.3%.
Phase IV trials held a 25.2% share in 2021, as against the five-year average of 27.6% and ten-year average of 29.1%. Phase III trials held a 20.2% share, compared with the five-year and ten-year averages of 18.9% and 17.0% respectively.
Phase I trials held a 14.9% share in 2021, over the five-year average of 8.3% and ten-year average of 7.5%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
